Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients With MYC Alterations
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs CUDC 907 (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Curis
- 03 Aug 2017 According to a Curis media release, interim results from this trial have been published.
- 22 Jul 2017 This trial has been suspended in Spain.
- 24 Jun 2017 This trial has been suspended in Germany.